Traditional corticosteroid inhalers for management of asthma symptoms require patients to squeeze and inhale in a coordinated maneuver. This is surprisingly difficult for many patients who end up receiving sub-optimal treatment. Teva Pharmaceutical, Israel’s big pharma firm, is now releasing in the RediHaler, the first breath-activated corticosteroid inhaler available in the U.S.
The RediHaler device doesn’t require any shaking or priming and comes with 120 doses per inhaler, the status of which can be checked via a visible counter. Two dosage strengths are available, 40 mcg and 80 mcg.
To use the device, the pumping and breathing doesn’t have to be coordinated. The patient simply inhales after preparing a dose, removing the timing factor altogether.